Real-world impact of drug-drug interactions (DDI): why complex HCV patients are preferentially treated with Sofosbuvir/Velpatasvir (SOF/VEL) over Glecaprevir/Pibrentasvir (GLE/PIB)

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Real-world impact of drug-drug interactions (DDI): why complex HCV patients are preferentially treated with Sofosbuvir/Velpatasvir (SOF/VEL) over Glecaprevir/Pibrentasvir (GLE/PIB)

	AASLD 2026 Denver